Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab in EBV Positive Metastatic Gastric Cancer
NCT03755440Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2018
- Primary completion
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in gastric cancer (GC), sponsored by Sun Yat-sen University. Started Dec 2018; status: completed.
02
Drugs
camrelizumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT03755440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03755440.